Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062732 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Domenico Galati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori-IRCCS-Fon…. Hauptthemen laut MEDLINE: Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematologic Neoplasms, Interleukin-3 Receptor alpha Subunit, Receptors, Immunologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing diseases and developing targeted therapies. Traditional treatment options for BPDCN have demonstrated limited effectiveness, highlighting the need for new and innovative therapeutic strategies. Recent advances in immunotherapy, particularly therapeutic monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapy, have provided promising alternatives. Tagraxofusp, the first FDA-approved CD123-targeted therapy, has significantly improved patient outcomes. Additionally, emerging CD303-targeting strategies offer the potential for further advancements. Despite these breakthroughs, challenges such as treatment resistance and toxicity remain. This review explores the latest developments in BPDCN treatment, emphasizing the potential of CD123 and CD303 as targets for precision medicine interventions. The ongoing evolution of targeted immunotherapies holds promise for improving patient survival and redefining treatment paradigms in hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
- Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, 80131 Napoli, Italy.
ORCID-Profile: Domenico Galati, Serena Zanotta, Fabrizia Florio, Sara Mele, Rosaria De Filippi, Antonio Pinto
Zitieren
APA
Galati, D., Zanotta, S., Florio, F., Mele, S., De Filippi, R., & Pinto, A. (2025). Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062732
Vancouver
Galati D, Zanotta S, Florio F, Mele S, De Filippi R, Pinto A. Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062732
BibTeX
@article{Galati2025,
author = {Galati, Domenico and Zanotta, Serena and Florio, Fabrizia and Mele, Sara and De Filippi, Rosaria and Pinto, Antonio},
title = {Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062732}
}
EUVIMED